Best initial treatments for patients with Cardiovascular-Kidney-Metabolic Syndrome.
Official title: Optimal first line therapies for patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome.
Funded at Veterans Health Administration · NIH-11046133 · Data updated 2026-11-12
This study is looking at the best first treatments for people with Cardiovascular-Kidney-Metabolic Syndrome and diabetes, comparing older options like metformin with newer medications to see which ones work better for keeping your heart and kidneys healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| NIH project number | 2I01CX000570-13 |
| Project ID | NIH-11046133 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 55 and older with new-onset diabetes and risk factors such as hypertension, obesity, and dyslipidemia.
✕Less likely to help
Patients without diabetes or those who already have established cardiovascular disease may not benefit from this research.
What this research studies
This research investigates the most effective first-line therapies for patients suffering from Cardiovascular-Kidney-Metabolic (CKM) Syndrome, particularly focusing on those with diabetes. It aims to compare traditional treatments like metformin with newer medications such as glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) to determine their effectiveness in preventing cardiovascular disease and kidney complications. The study will utilize a national longitudinal approach, gathering data from patient reports, clinical records, and laboratory results to assess treatment outcomes over time.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that significantly reduce the risk of cardiovascular and kidney complications for patients with CKM Syndrome.
How similar studies have gone: Previous research has shown promising results with GLP1RA and SGLT2i in patients with pre-existing cardiovascular disease, but this specific comparison in high-risk, drug-naïve patients is relatively novel.
Where this research is happening
-
Veterans Health Administration
Nashville, United States Active
Researchers
- Principal investigator: Roumie, Christianne L. — Veterans Health Administration
- Study coordinator: Roumie, Christianne L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.